The United States and United Kingdom Agree to Duty-Free Accord on Pharmaceuticals.
Britain and America have signed a important trade agreement that will ensure no import taxes on UK medicine shipments being sold in the American market.
The Terms of the Accord
In exchange for the tariff guarantee, the UK has committed to raise spending on drugs through the NHS. This move ensures that duties on these crucial exports will stay at nothing for a period of 36 months.
This deal comes after earlier threats to hike duties on patented drug products, with potential rates mentioned up to double the cost.
"This deal with the United Kingdom reinforces the worldwide climate for cutting-edge drugs and establishes long-overdue fairness to transatlantic pharmaceutical trade," a release noted.
Trade Impact
Medicines are one of the the United Kingdom's most significant goods shipped to the America, which is easily the primary buyer for large British pharmaceutical firms.
Export figures reveal that in the 12 months to the end of last September, the UK shipped medicines totaling billions to the US. This figure made up a significant portion of total UK exports in that timeframe.
"This agreement protects employment, stimulates capital expenditure and sets the stage for the UK to emerge as a worldwide center for biotech and pharma," a minister stated.
Specific UK Commitments
The pact involves several key changes from the British government:
- Price Threshold Increase: The UK will raise the cost ceiling at which it considers new treatments to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a goal to raise total public funding on drugs from 0.3% of GDP to 0.6 percent over the next decade.
- Payback Limit: The sum drug companies must return to the NHS to stay within budget will be restricted at 15%. Previously, refunds topped twenty percent.
Industry Background
This agreement comes amid a ongoing tension between the drug companies and the UK government over drug pricing and NHS adoption.
This friction were exacerbated by claims that US consumers were charged a premium for the same drugs than consumers in the Britain and the EU.
Over the last 18 months, several significant drug company projects in the UK have been halted or cancelled, while major investments have been directed toward US facilities.
The Science Minister acknowledged that the NHS had to increase expenditure on treatments, noting that its spending on drugs had decreased as a share of its overall budget over the previous ten-year period.